JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Kai Kupferschmidt

2 papers in the library · 15 citations · publishing 2024

Papers

Sort Most recent Most cited

What's next for psychedelics after MDMA rejection?

Science (New York, N.Y.) August 16, 2024 Kai Kupferschmidt 12 citations

Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.

DOI: 10.1126/science.ads4470 Full text Psychedelic medicine Mental health treatments Pharmaceutical research Drug development +1

Psychedelics field looks ahead after FDA advisers' rejection.

Science (New York, N.Y.) June 14, 2024 Kai Kupferschmidt 3 citations

Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.

DOI: 10.1126/science.adr0286 Full text Psychedelic-medicine MDMA-Therapy Clinical-trials Drug-regulation +1